The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISHL HL Update 2021 | Next steps for older patients with HL
Jonathan Friedberg, MD, University of Rochester, Rochester, NY, outlines future directions in the treatment and management of older patients with Hodgkin lymphoma (HL) including enrollment of this patient population in clinical trials and reducing chemotherapy to mitigate toxicities seen in older patients, for example with the use of checkpoint inhibitors. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
